Clinical Trials Directory

Trials / Conditions / PSA Progression

PSA Progression

18 registered clinical trials studyying PSA Progression — 1 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingMRI-Assisted Guidance for Non-Essential Tissue Sampling
NCT07516223
Shanghai East HospitalN/A
Active Not RecruitingWhite Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Pro
NCT04519879
City of Hope Medical CenterPhase 2
WithdrawnEnzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
NCT03709550
Roswell Park Cancer InstitutePhase 1 / Phase 2
CompletedGallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prosta
NCT03698370
Andrei IagaruPhase 2
CompletedApalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
NCT03503344
University of California, San FranciscoPhase 2
UnknownsEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04033432
Northwestern UniversityPhase 2
CompletedEnzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
NCT03751436
Roswell Park Cancer InstitutePhase 1
Active Not RecruitingStereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Su
NCT03541850
Jonsson Comprehensive Cancer CenterPhase 2
TerminatedDocetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Pros
NCT03442556
University of WashingtonPhase 2
CompletedPembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate C
NCT03406858
Barbara Ann Karmanos Cancer InstitutePhase 2
Completed68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
NCT04050215
Jonsson Comprehensive Cancer CenterPhase 2
CompletedESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03456804
Barbara Ann Karmanos Cancer InstitutePhase 2
Active Not RecruitingAbiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in
NCT02703623
M.D. Anderson Cancer CenterPhase 2
CompletedDocetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containin
NCT02598895
University of WashingtonPhase 2
Active Not RecruitingPembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated Wit
NCT02312557
OHSU Knight Cancer InstitutePhase 2
TerminatedSelinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-R
NCT02215161
University of California, San FranciscoPhase 2
CompletedMolecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant
NCT02228265
OHSU Knight Cancer Institute—
No Longer AvailableF18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
NCT03501940
Andrei Iagaru—